Organoid Sciences
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Organoidsciences develops miniature three-dimensional tissue structures, called organoids, that closely mimic human organs, and uses them to create regenerative therapies and drug-testing tools.
Its customers include pharmaceutical and cosmetics companies seeking more accurate alternatives to conventional cell and animal testing, as well as hospitals using its precision-medicine service to match cancer patients with the most suitable immunotherapy drugs. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company operates across four business lines: regenerative therapeutics, a new-material evaluation service, a research-reagent product range, and contract development and manufacturing.
Summary is AI-generated and may contain errors · figures from DART filings
The Korean government's Ministry of Trade, Industry and Energy has formally designated the company's organoid-based regenerative therapy technology as a national advanced strategic technology under Korean law.
Organoid Sciences in five facts
What does Organoid Sciences do?
Organoidsciences develops miniature three-dimensional tissue structures, called organoids, that closely mimic human organs, and uses them to create regenerative therapies and drug-testing tools.
Where is Organoid Sciences listed and in which sector?
Organoid Sciences (Korean name: 오가노이드사이언스) trades under KRX code 476040 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Organoid Sciences?
Its market capitalisation was US$30.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Organoid Sciences's latest annual revenue and operating profit?
For fiscal year 2025, Organoid Sciences reported revenue of US$1.8M, an operating loss of US$12.2M and a net loss of US$11.9M, per its annual report on DART (data retrieved from DART on 2026-06-04).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Grant of stock optionsOct 6
- Grant of stock optionsAug 31
- Securities issuance results (voluntary)Capital raise · May 7
- Material event report (rights offering)
Organoid Sciences disclosed convertible bonds to raise US$4.07M, about 12.7% of its market value.
Capital raise · Apr 30 - Material event report (convertible bonds)
Organoid Sciences disclosed convertible bonds to raise US$16.1M, about 50.8% of its market value.
Capital raise · Apr 29 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Organoid Sciences updated its previously filed consolidated results for FY2025: revenue of US$1.63M (+23.2% year on year), an operating loss of US$11M and a net loss of US$10.7M.
Earnings · Mar 11 · 2 versions